CV-159, a unique dihydropyridine derivative, prevents TNF-induced inflammatory responses in human umbilical vein endothelial cells

Journal of Pharmacological Sciences

Volumn 113, Issue 2, 2010, Pages 182-191

  Usui, Tatsuya ^a   Yamawaki, Hideyuki ^a   Kamibayashi, Masato ^b   Okada, Muneyoshi ^a   Hara, Yukio ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Dihydropyridine derivative; Inflammation; Reactive oxygen species; Signal transduction; Vascular endothelium

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (3 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 3 METHYL 5 [6 (5 PHENYL 3 PYRAZOLYLOXY)HEXYL] ESTER; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; DICHLORODIHYDROFLUORESCEIN DIACETATE; DIHYDROPYRIDINE DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; CALCIUM CHANNEL BLOCKING AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PROTEIN EXPRESSION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; ATHEROSCLEROSIS; CELL CULTURE; CHEMICAL PHENOMENA; CYTOLOGY; DRUG EFFECTS; FEMALE; METABOLISM; PHOSPHORYLATION;

ATHEROSCLEROSIS; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; DEPRESSION, CHEMICAL; DIHYDROPYRIDINES; E-SELECTIN; ENDOTHELIAL CELLS; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 77953876912     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10033FP     Document Type: Article

References (29)

1. Umekawa H, Yamakawa K, Nunoki K, Taira N, Tanaka T, Hidaka H. Inhibition of calmodulin function by CV-159, a novel dihydropyridine compound. Biochem Pharmacol. 1988;37:3377-3381.
2. Kamibayashi M. CV-159. Drugs Fut. 1989;14:206-210.
3. Miyazaki H, Tanaka S, Fujii Y, Shimizu K, Nagashima K, Kamibayashi M, et al. Neuroprotective effects of a dihydropyridine derivative, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarbox ylic acid methyl 6-(5-phenyl-3-pyrazolyloxy) hexyl ester (CV-159), on rat ischemic brain injury. Life Sci. 1999;64:869-878.
4. 2+ antagonist, CV159, in hepatic I/R injury-the evaluation of hepatic organ reducing activity using in vivo and ex vivo EPR. J Surg Res. 2008;145:49-56.
5. Kobayashi HP, Watanabe T, Oowada S, Hirayama A, Nagase S, Kamibayashi M, et al. Effect of CV159-Ca(2+)/calmodulin blockade on redox status hepatic ischemia-reperfusion injury in mice evaluated by a newly developed in vivo EPR imaging technique. J Surg Res. 2008;147:41-49.
6. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
7. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
8. Elahi MM, Matata BM. Free radicals in blood: evolving concepts in the mechanism of ischemic heart disease. Arch Biochem Biophys. 2006;450:78-88.
9. Iwanami M, Shibanuma T, Fujimoto M, Kawai R, Tamazawa K, Takenaka T, et al. Synthesis of new water-soluble dihydropyridine vasodilators. Chem Pharm Bull. 1979;27:1426-1440.
10. Yamawaki H, Saito K, Okada M, Hara Y. Methylglyoxal mediates vascular inflammation via JNK and p38 in human endothelial cells. Am J Physiol Cell Physiol. 2008;295:C1510-C1517.
11. Baden T, Yamawaki H, Saito K, Mukohda M, Okada M, Hara Y. Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium. Biochem Biophys Res Commun. 2008;373:253-257.
12. Mukohda M, Yamawaki H, Okada M, Hara Y. Methylglyoxal enhances sodium nitroprusside-induced relaxation in rat aorta. J Pharmacol Sci. 2010;112:176-183.
13. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with imageJ. Biophotonics International. 2004;11:36-42.
14. Rong Y, Doctrow SR, Tocco G, Baudry M. EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology. Proc Natl Acad Sci U S A. 1999;96:9897-9902.
15. Boyle EM Jr, Kovacich JC, Canty TG Jr, Morgan EN, Chi E, Verrier ED, et al. Inhibition of nuclear factor-kappa B nuclear localization reduces human E-selelectin expression and the systemic inflammatory response. Circulation. 1998;98:II282-II288.
16. Ohno O, Shima Y, Ikeda Y, Sakurai K, Watanabe K, Kawai Y, et al. Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow. Oncol Res. 2005;15:189-197.
17. Lin CW, Chen LJ, Lee PL, Lee CI, Lin JC, Chiu JJ. The inhibition of TNF-alpha-induced E-selectin expression in endothelial cells via the JNK/NF-kappaB pathways by highly N-acetylated chitooligosaccharides. Biomaterials. 2007;28:1355-1366.
18. Buss H, Dorrie A, Schmitz ML, Hoffmann E, Resch K, Kracht M. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem. 2004;279:55633-55643.
19. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension. 2004;43:263-269.
20. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest. 1981;68:1366-1369.
21. Bernini F, Catapano AL, Corsini A, Fumagalli R, Paoletti R. Effects of calcium antagonists on lipids and atherosclerosis. Am J Cardiol. 1989;64:129I-133I;discussion 133I-134I.
22. Henry PD. Atherogenesis, calcium and calcium antagonists. Am J Cardiol. 1990;66:3I-6I.
23. 2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur J Pharmacol. 2004;498:303-314.
24. Cominacini L, Pasini AF, Pastorino AM, Garbin U, Davoli A, Rigoni A, et al. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. J Hypertens. 1999;17:1837-1841.
25. Shima E, Katsube M, Kato T, Kitagawa M, Hato F, Hino M, et al. Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens. 2008;21:78-84.
26. 2-induced cell death in neonatal rat cardiomyocytes. Cardiovasc Drugs Ther. 2007;21:69-72.
27. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol. 1999;31:275-281.
28. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-580.
29. Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol. 1999;33:242-249.